Radioprotection, radiomitigation and radiorecovery

Abstract

Radioprotection, Radiomitigation and Radiorecovery: Timed use of more widely available antiradiation agents in a kit for subjects affected by ionizing radiation, radiomimetic exposure and radiocontamination. The method in the form of strategically timed preemptive and postirradiation compositions; radioprotection, radiomitigation and radiorecovery formulations are comprised of various available anticorporation, antioxidant, decorporation, multi-mechanistic, pro-survival, pro-hematopoietic, anti-fibrotic and other novel ingredients in synergistic mixtures to be used in critically-timed manners. Radioprotection, radiomitigation and radiorecovery of a mammal prior to, during, just after or well-after exposure to ionizing radiation energyalpha, beta, neutron, gamma, X-ray and damaging radiofrequency radiationfor long or short periods of time, and exposure to or contamination by radioactive elements or compounds such as radioiodine, radiostrontium, radiophosphorus, radiocobalt, radiocadmium, radiopollonium, radioradium, radiocesium, radiouranium, radioamericium, radiopollonium, radiocerium, radioindium, and the like. Radiomimeticprotective method for mucosal exposure is also described.

Claims

1. A method for anticorporation and/or decorporation treatment, comprising administering to a subject population in need thereof, a formulated composition, said composition comprising a therapeutically effective amount of up to about 350 mg sodium ferrocyanide, wherein; said sodium ferrocyanide can be administered dry or water-dissolved; said sodium ferrocyanide is at a minimum USP purity; said treatment may be administered preemptively before contamination occurs as anticorporation; said treatment may be administered after contamination as decorporation; said composition is suitable for oral, dermal or external use; said treatment method produces low toxicity; said subjects are exposed to radioisotopes or non-radioisotopes; if the patient has been exposed to radioisotopes said administration administered until two times background radiation or less is achieved, and; wherein if the subject is exposed to radioisotopes the treatment reduces ill effects of radioisotope exposure.

2. The method of claim 1 whereby said formulation, in order to enhance decorporation, is optionally combined with a therapeutically-effective amount of at least one other agent selected from the group consisting of: activated charcoal, ammonium perchlorate, Attapulgite, Bentonite clay, calcium alginate, chlorella, ethylenediaminetetraacetic acid, French Green clay, Fuller's Earth, green tea extract, Montmorillonite clay, Pascalite, psyllium husk powder, citric acid, and Zeolite.

3. The method of claim 2 whereby said decorporation is of at least one of cesium, strontium, uranium, and thallium.

4. The method of claim 1 whereby, said formulation, in order to enhance anticorporation, is optionally combined with a therapeutically-effective amount of at least one other agent selected from the group consisting of calcium citrate, magnesium citrate, sodium iodate, potassium iodide, phospho-soda, potassium phosphate, vitamin B12, and aluminum hydroxide.

5. The method of claim 4 whereby said anticorporation may be of at least one of iodine, cobalt, strontium, phosphorus, calcium, uranium, thallium, or cesium.

6. The method of claim 1 whereby said sodium ferrocyanide is administered via a fibrous wetted durable textured disposable towelette with optional ink tracer for external or dermal use.

7. The method of claim 1 whereby said sodium ferrocyanide has a higher chelation and lower toxicity on a weight basis as compared to Prussian Blue.

8. The method of claim 1 whereby said sodium ferrocyanide when added to up to 5 g calcium alginate exhibits specific synergy for decorporation.

Description

DETAILED DESCRIPTION OF THE INVENTION

(1) The following examples of formulations are not delimitors to all possibilities. Dosages and selection of the agents used in accordance with the invention depend on age, weight, clinical condition of the recipient patient, type of radiation or radiocontamination and Judgment of practitioner administering therapy. radioprotection, radiomitigation or radiorecovery.

(2) All applications are intended for non-topical administration, oral administration is the preferred route to introduce agents for therapeutic benefit. Preferred dosage forms include powders to be mixed into foods and drinks, powders to be diluted and then mixed into drinks, capsules, wafers, nanoparticles, dragees, syrups, suspensions, elixers, lozenges, pills, troches, sublinguals, buccals, nasal spray rectal doses, chewing gum, lollipops, dissolving thin-films, pastilles, gelatins, designer foods, drink mixes, puddings, cereals, juices, smoothies, fizzy-drinks, etc. All topical formulations may be oil-in-water or water-in-oil emulsions, gels, lotions, liquids, creams, pastes, washes, suspensions, lotions, ointments or designed as micelles, nanoparticles, liposomes or microparticles. Excipients in formulations may be inert waxes, polymers, sugars, etc. such as PEG-s, polysorbate-s, waxes, celluloses, fats, and any other accepted excipient.

(3) (Example 1) A synergistic timed-use pre-irradiation radioprotection formulation in divided capsules containing 200 g selenomethionine, 300 mg R-alpha lipoic acid, 600 mg N-acetyl cysteine, 500 mg vitamin C, 400 IU vitamin E nicotinate, and 50,000 IU beta-carotene and 6 grams/day Ocimum sanctum. The formulation is optimally used daily for 5 days or more prior to irradiation, and stopped just prior to radiation exposure.

(4) (Example 2) A post-irradiation radiomitigation antioxidant and other mechanism formulation comprised of 200 g selenomethionine, 150 mg R-alpha lipoic acid, 600 mg N-acetyl cysteine, 500 mg vitamin C, 400 IU vitamin E nicotinate, and 50,000 IU beta-carotene, 550 mg rose hips, 2 g Ginkgo biloba and 200 mg CoQ10. The post-irradiation radiomitigation formulation is to be started 24 hours after cessation of radiation exposure.

(5) (Example 3) A anticorporation radioprotection formulation of divided dry encapsulated formula containing 2.5 g calcium carbonate, 5,000 IU vitamin D3, 3.6 g magnesium citrate (400 mg magnesium), 210 mg zinc gluconate (30 mg zinc) and a separate sublingual dose of vitamin B12 2.5 mg. The use is timed optimally for pre-exposure to cobalt-60, radiozinc, radioradium and radiostrontium A prefilled cylinder with 155 mg sodium iodate is diluted qs 100 mL with water and dosed according to TABLE 2.

(6) (Example 4) A radiomimetic gingival treatment protectant gel for use prior to peroxide dental whitening procedures (expressed as % by weight): glycerin 42.0+poloxamer 18+ascorbic acid 2.0+sodium lauryl sulfate 1.2+natural peppermint oil 1.0+alpha tocopheryl nicotinate 2.0+superoxide dismutase 1+Sea Buckthom oil 4.0+Glutathione 2.0+coloring agent 0.10+deionized water balance+xylitol sweetener.

(7) (Example 5) A radiodermal protective lotion comprised in w/v % of 32% almond oil, 17% coconut oil, 16% beeswax, 6.5% SOD, 9.7% SBO, 9.7% bromelain, 3.2% DFMO, 6.5% SOD. The use is timed for application no more than three hours prior to radiotherapy exposure, and may be enhanced with an occlusive barrier such as cellophane wrap. The lotion is wiped and cleaned off entirely just prior to irradiation. Local cooling of tissues prior to irradiation to as low as safely possible affords even greater radioprotection.

(8) (Example 6) A radiomitigation decorporation packet containing divided capsules with 3 g calcium citrate, 2 g green tea extract, 1.2 g aluminum hydroxide, 250 mg phospho-soda. Also contained in the packet is an envelope of dried 5 g calcium alginate granules, psyllium husk powder 10 g, chlorella 10 g, and bentonite 5 g for use as a granola or smoothie additive. The formulation is to be used until ALARA conditions (as low as reasonably achievable) or two times background radiation for a radiocontaminated patient.

(9) (Example 7) A radiorecovery prohematopoietic formulation in divided capsules with 7.5 mg chelated manganese, 50 mg chelated copper, 65 mg ferrous sulfate, 50 mg zinc gluconate, 25,000 IU vitamin A, 3 g Ginkgo extract, 400 mcg folacin, 50 mg pyridoxine, 3 g Chaga extract, 150 mg 4-androstenedione. The formulation is taken once a day beginning within the first 24 hours post-irradiation and continuing for 5 days with repeated tests for blood status.

(10) (Example 8) A radiorecovery antifibrotic formulation in divided capsules with 3 g rosemary extract, 4 g bromelain, 35 mg glabridin, and separate capsules for flaxseed oil 4 g. The formulation is to be started after day 5 post-irradiation.

(11) (Example 9) An emergency field- or hospital-use radiomitigation tracer external decorporation clay-wipe made of a fibrous wetted durable textured paper towelette containing in the wetting solution in w/v % 80% water, PEG 4%, citric acid 0.9%, indigo dye 1%, Bentonite Clay 15%. Claim 9 is used after external radiocontaminatiotin a swipe and lift; the pass leaves a slight blue dye stain on the skin to indicate that this area has been cleaned and avoid cross-contamination; towelettes are not to be reused.

(12) Radiocontaminated used towelettes must be disposed of in proper containers for radiological hazards. Patients must be reminded not to eat, smoke, drink, lick lips while externally radiocontaminated. Ideally hair should be clipped but not shaved and shampooed multiple times. Check patient for ALARA, usually double background radiation, map body locations of contamination for further treatment.

(13) (Example 10) A general radioprotection or radiomitigation method for protecting from or mitigating radiation damage consisting essentially of administering, either prior to radiation exposure or pretreating for radioprotection, or after radiation exposure for radiomitigation, to a subject in need thereof, a therapeutically effective amount for best results of a synergistic core formulation consisting of about up to 600 mg/day of R-alpha lipoic acid, up to about 15 grams per day of extract of Hippophae rhamnoides, up to about 15 grams per day of extract of Mentha arvensis, up to about-1.2 grams per day of N-acetyl cysteine, up to about 2 grams per day of rose hips rose hips, and up to about 800 IU per day vitamin E nicotinate, and whereby:

(14) i. said treatment treats radiation energy exposure, radioisotope exposure, and radiomimetic chemical exposure, and effects radioprotection antioxidant, DNA-protection and pro-survival and radiomitigation post-irradiation, as well as DNA-repair and anti-RIBEs (radiation-induced bystander effects) benefits, and
ii. said formulation for radioprotection may be labeled a Type I or Type I-b, I-d and I-e countermeasure or general radioprotection formulation, and for radiomitigation said formulation may be labeled a Type II or Type II-b, II-c, and II-d countermeasure or a general radiomitigation formulation.

(15) (Example 11) The formulation of Example 10 for general radioprotection treatment whereby said formulation may be further synergistically-combined with a therapeutically effective amount for best results, of at least one other agent selected from but not limited to the group consisting of:

(16) i. alpha-difluoromethylornithine, aminothiols, beta carotene, bromelain, chlorella, cooling of tissues, hydration, CoQ10, dimethylsulfoxide, extract of Emblica officinalis (Gooseberry), extract of Ganoderma lucidum, glabridin, extract of goji berry, glutathione, extract of Inonotus obliquus (Chaga), extract of Occimum santctum, papain, phenylbutyrate, extract of Rosmarinus officinalis, selenomethionine, vitamin A (retinol), vitamin C, and vitamin D3, and
i. said treatment is begun pre-exposure and pre-treats the consequences of radiation energy exposure, radioisotope exposure, and radiomimetic chemical exposure and effects radioprotection antioxidant, DNA-protection and pro-survival benefits, and
ii. said administration may include but is not limited to that of the dermis in a dermal formulation or to the mucosal tissues, and dosages, and
iii. said formulation for radioprotection may be labeled a Type I or Type I-b, I-d and I-e countermeasure or general radioprotection countermeasure formulation.

(17) (Example 12) The formulation of Example 10 for a general radiomitigation post-exposure treatment whereby said formulation may be further synergistically combined with a therapeutically effective amount for best results, of at least one other agent selected from but not limited to the group consisting of: beta carotene, CoQ10, dimethylsulfoxide (DMSO), extract of Ginkgo biloba, phenylbutyrate, selenomethionine, and vitamin C, whereby

(18) i. said administration is begun post-exposure and optimally begun before radiation symptoms arise, and

(19) ii. said treatment treats the consequences of radiation energy exposure, radioisotope exposure, and radiomimetic chemical exposure and effects radiomitigation post-radiation, DNA-repair and anti-RIBEs (radiation-induced bystander effects) benefits, and

(20) iii. said administration may include but is not limited to that of the dermis in a dermal formulation or to the mucosal tissues, and

(21) iv. said formulation may be labeled a Type II or a Type II-b, II-c, and II-d countermeasure or a general radiomitigation formulation.

(22) (Example 13) An anticorporation radioprotection method for protecting from radioisotope damages comprised of pretreating or administering prior to radiocalcium, radiostrontium and radiophosphorus or other radioisotope exposure to a subject in need thereof a therapeutically effective amount for best results of a formulation of about up to 6 grams per day of calcium citrate, and whereby:

(23) i. calcium citrate is an anticorporation agent against radioisotope uptake, and

(24) ii. said treatment is begun pre-exposure and pre-treats the consequences of radioisotope exposure and effects pre-exposure anticorporation or blocking benefits, and

(25) iii. said formulation may be labeled a Type I-c countermeasure or radioprotection anticorporation formulation.

(26) (Example 14) The anticorporation method of Example 13 whereby said formulation may be further synergistically combined with a therapeutically effective amount for best results of at least one other agent selected from but not limited to the group consisting of: potassium phosphate, aluminum hydroxide, calcium alginate, ammonium perchlorate, sodium iodate, zinc gluconate, vitamin D3, calcium carbonate, psyllium, and magnesium citrate, and

(27) i said formulation may be labeled a Type I-c countermeasure or radioprotection anticorporation formulation.

(28) (Example 15) A decorporation radiomitigation method for treating radiocontamination comprised of administering, after exposure to a radioisotope, to a subject in need thereof, a formulation comprising a therapeutically effective amount for best results, of about up to 350 mg/day sodium ferrocyanide, and whereby:

(29) i. sodium ferrocyanide has a lower toxicity and higher chelation affinity than ferric ferrocyanide (Prussian Blue), and

(30) ii. said formulation may be further comprised of a fibrous wetted durable textured disposable towelette with optional ink tracer for external or dermal use, and

(31) iii. said formulation may be labeled a Type II-a countermeasure or a radiomitigation decorporation formulation.

(32) (Example 16) The decorporation method of Example 15 whereby said formulation may be further synergistically combined with a therapeutically effective amount for best results, of at least one other agent selected from but not limited to the group consisting of: activated charcoal, aluminum hydroxide, ammonium perchlorate, Attapulgite, Bentonite clay, calcium alginate, calcium citrate, chlorella, ethylenediaminetetraacetic acid, French Green clay, Fuller's Earth, green tea extract, Montmorillonite clay, Pascalite, phospho-soda, potassium phosphate, psyllium husk powder, rose hips, sodium iodate, vitamin C, vitamin D3, and Zeolite, and

(33) i. said formulation may be further comprised of a fibrous wetted durable textured disposable towelette with optional ink tracer for external or dermal use, and

(34) ii. said formulation may be labeled a Type II-a countermeasure or a radiomitigation decorporation formulation.

(35) (Example 17) A radiorecovery method for treating radiation exposure consisting essentially of administering after radiation exposure to a subject in need thereof a synergistic formulation comprised of a therapeutically effective amount for best results, of about up to 15 grams per day of extract of Angelica sinensis, up to about 4 grams per day of extract of Ganoderma lucidum, up to about 50 mg/kg or 25,000 IU vitamin A per day, up to about 4 grams per day of extract of Inonotus obliquus (Chaga), and up to about 800 IU vitamin E/day, and whereby

(36) i. said exposure includes radiation energy exposure, radioisotope exposure, and radiomimetic chemical exposure, and

(37) ii. said treatment treats the consequences of radiation energy exposure, radioisotope exposure, and radiomimetic chemical exposure and effects medical benefits against acute radiation syndrome, hematopoietic damage, spleen damage, and burns, and effects anti-fibrosis and anti-inflammation and anticancer radiorecovery benefits, and
iii. said formulation may be labeled a general Type III countermeasure or a general radiorecovery formulation.

(38) (Example 18) The formulation of Example 17 for medical radiorecovery post-exposure treatment whereby said formulation may be further synergistically combined with a therapeutically effective amount for best results, of at least one other agent selected from but not limited to the group consisting of: alpha-difluoromethylornithine, 4-androstenedione, extract of goji berry, extract of Grifola frondosa, extract of Hippophae rhamnoides, extract of Inonotus obliquus, and vitamin C, whereby:

(39) i. said treatment treats the consequences of radiation energy exposure, radioisotope exposure, and radiomimetic chemical exposure and effects benefit against medical acute radiation syndrome, hematopoietic damage, spleen damage, and burns, and

(40) ii. said formulation may be labeled a Type II-a countermeasure or a medical radiorecovery formulation.

(41) (Example 19) The formulation of Example 17 for anti-fibrosis and anti-inflammation radiorecovery post-exposure treatment, whereby said formulation may be further synergistically combined with a therapeutically effective amount for best results, at least one other agent selected from but not limited to the group consisting of: dimethylsulfoxide, and extract of Rosmarinus officinalis, flaxseed oil, glabridin, extract of Hippophae rhamnoides, phenylbutyrate, and vitamin C, whereby:

(42) i. said treatment treats the consequences of radiation energy exposure, radioisotope exposure, and radiomimetic chemical exposure and effects radiorecovery benefits against delayed post-exposure inflammation and fibrotic sequelae, and

(43) ii. said formulation may be labeled a Type III-b countermeasure or a delayed post-exposure inflammation and fibrotic sequelae radiorecovery formulation.

(44) (Example 20) The formulation of Example 17 for anti-cancer radiorecovery post-exposure treatment whereby said formulation may be further synergistically combined with a therapeutically effective amount for best results of at least one other agent selected from but not limited to the group consisting of: dimethylsulfoxide, extract of Inonotus obliquus (Chaga), and vitamin C, whereby:

(45) i. said treatment treats the consequences of radiation energy exposure, radioisotope exposure, and radiomimetic chemical exposure and effects radiorecovery benefits against cancer, and

(46) ii. said formulation may be labeled a Type III-c countermeasure or an anticancer radiorecovery formulation.

(47) (Example 21) A synergistic radioprotection, radiomitigation and radiorecovery radiation countermeasure kit for treating consequences of radiation energy exposure, radioisotope exposure, and/or radiomimetic chemical exposure, whereby said kit elements consist of instructions and apparatus for administering the kit formulations and at least one of:

(48) i. a pre-exposure general radioprotection formulation such as in Examples 10 and 11 herein which effects antioxidation, DNA protection and pro-survival benefits, and which may be labeled Type I-b, I-d, and I-e countermeasures, respectively, and

(49) ii. a post-exposure general radiomitigation formulation such as in Examples 10 and 12 herein which effects post-radiation, DNA repair and anti-RIBES benefits, and which may be labeled Type II-b, II-c and II-d countermeasures, respectively, and

(50) iii. a pre-exposure anticorporation radioprotection formulation such as in Examples 13 and 14 herein which effects radioisotope anticorporation or blocking benefits, and which may be labeled a Type I-c countermeasure, and

(51) iv. a post-exposure decorporation radiomitigation formulation such as in Examples 15 and 16 herein which effects decorporation benefits, and which may be labeled a Type II-a countermeasure, and

(52) v. a post-exposure medical radiorecovery formulation such as in Examples 17 and 18 herein, which effects medical, Acute Radiation Syndrome (ARS), pro-hematopoietic, anti-spleen damage, anti-burn, and anti-infection benefits, and which may be labeled a Type III-a countermeasure, and
vi. a post-exposure anti-inflammatory and anti-fibrotic radiorecovery formulation, such as in Examples 17 and 19 herein, which effects delayed anti-inflammatory and anti-fibrotic sequelae benefits, and which may be labeled a Type III-b countermeasure, and
vii. a post-exposure anticancer radiorecovery formulation, such as Examples 17 and 20 herein, which effects anticancer benefits, and which may be labeled a Type III-c countermeasure, and
viii. radioprotection, radiomitigation and radiorecovery elements may be labeled Type I, Type II and Type III countermeasures, respectively, and whereby
ix. said consequences of exposure may be comprised of one or more of oxidative damages, DNA damage, morbidity and mortality, radiocontamination, radiation-induced bystander effects or RIBES, acute radiation syndrome or ARS, hematopoietic damage, spleen damage, burns, and infection, delayed inflammatory and fibrotic sequelae and cancer.
x. A pro-hematopoietic method of treating hematopoietic damage comprised of administering to a subject in need thereof a therapeutically effective amount for best results of about up to 300 mg/day of the pro-hematopoietic agent 4-androstenedione.

(53) (Example 22) A critically timed-use synergistic Type 1-b and Type 1-e pre-irradiation radioprotection method comprising the administration to an individual an effective amount of a synergistic combination of multiple-mechanism agents: selenomethionine, alpha-lipoic acid, N-acetyl cysteine, vitamin C, beta-carotene and vitamin E nicotinate,

(54) (Example 23) The preceding core composition of Example 22 in addition to at least one or more of the following survival-data radioprotectives in the form of an extract or whole herb or chemical: Aegle marmelos (Bael), Ageratum conyzoides (Chickweed), Amaranthus paniculatus (Foxtail Amaranth), Angelica Sinensis (Dong Quai), Chlorella, Emblica officinalis (Indian Gooseberry), Hippophae rhamnoides (Sea Buckthom), Iodine (as NaIO 3 or Kl), Lycium chinense (Goji berry), Menta Arvensis (Wild mint), Moringa oleifera (Moringa), Ocimum sanctum (Holy Basil), Papain, Famotidine, Silybum marianum (Milk Thistle), Trifolium subterraneum (Subclover), Trifolium pretense (Red Clover), Syzgium cumini (Jamun), Tinospora cordifolia (Guduchi), Zingiber officinale (Ginger), Phenylbutyrate.

(55) (Example 24) The method of Example 22 comprising an effective dose of up to: 400 g selenomethionine, 600 mg R-alpha lipoic acid, 1200 mg N-acetyl cysteine, 1000 mg vitamin C, 800 IU vitamin E nicotinate, and 100,000 IU beta-carotene.

(56) (Example 25) The method of Example 22 consisting of the preceding core composition with the addition of up to 15 grams/day each of any one or more survival-data radioprotective herbs or herbal extracts, up to 30 mg/day NaIO 3 or Kl, up to 40 mg/day famotidine and up to 30 g/day phenylbutyrate.

(57) (Example 26) The method of Example 22_optimally taken twice a day for a minimum of one day for low dose exposure, up to optimally five days or more prior to significant diagnostic irradiation, but not radiotherapy, stopping dosing just before irradiation. Claim 4 of [0085] radioprotection method is to be formulated in any oral dosage form; as a suspension, tablets or capsules, in water, soda, soft drink or fruit juice, food, confection or dry powder and the like.

(58) (Example 27) A synergistic, timed-use, Type 11-b post-irradiation radiomitigation maintenance method comprising the administration to an individual an effective amount of a combination of selenomethionine, alpha-lipoic acid, N-acetyl cysteine, vitamin C, beta-carotene and vitamin E nicotinate, and at least one of Ginkgo biloba (Ginkgo) and Hippophae rhamnoides (Sea Buckthorn) extracts, rosehips, CoQ10.

(59) (Example 28) The method of Example 27 comprising an effective dose up to: 400 g selenomethionine, 600 mg R-alpha lipoic acid, 1200 mg N-acetyl cysteine, 1000 mg vitamin C, 800 IU vitamin E nicotinate, and 100,000 IU beta-carotene.

(60) (Example 29) The method of Example 28 consisting of the preceding core composition with the addition of up to 2000 mg rose hips, up to 15 grams each of Ginkgo biloba (Ginkgo) and Hippophae rhamnoides (Sea Buckthorn) extracts, and up to 400 mg CoQ10.

(61) (Example 30) The method of Example 28 comprising administering to an individual the composition daily starting 24 hours post radiation exposure, for continued general radioprotection, especially for occupational workers such as flight crews, soldiers, radiodiagnosticians and the like, or for general health in a radiopolluted environment.

(62) (Example 31) A timed-use, Type 1-c pre-irradiation radioprotection anticorporation method comprising a comprehensive formulation for the simultaneous blockade of uptake of cobalt-60, strontium-90, or zinc-65, from in vivo milieu of subjects affected by the exposure to nuclear radiocontamination. Said compositions of [0094] being made up of vitamin B12, calcium carbonate, and vitamin D3, zinc gluconate with the possible addition or co-administration with sodium iodate.

(63) (Example 32) The method of Example 31 comprising an effective daily dose of each up to: 5 mg sublingual vitamin B12, 2 grams calcium in calcium carbonate (5.0 g), 10,000 IU vitamin D3, 800 mg magnesium in magnesium citrate (7.1 g), 60 mg zinc in zinc gluconate (420 mg) in any oral dosage form.

(64) (Example 33) The method of Example 31 consisting of the preceding core composition with the possible addition or co-administration with sodium iodate at a maximal adult daily dose of 155 mg/day.

(65) (Example 34) The method of Example 31 wherein said component of sodium iodate is delivered in the form of 155 mg of dry USP pure chemical inside of 100 milliliter fillable graduated syringe device, to be diluted by consumer and dosed as a liquid for precise dosing.

(66) Sodium iodate may take the form of oral dosage forms such as a suspension, beverages, confection or dry powder and the like.

(67) (Example 35) A synergistic timed-use method of preventing injury from dental radiomimetic bleaching agents. The composition being used before radiomimetic cosmetic dental application of tissue-damaging tooth-whitening peroxides comprising the administration to the oral gingival tissue an effective amount of the combination of glutathione (GSH), superoxide dismutase (SOD), vitamin C, vitamin E nicotinate and Sea Buckthorn oil.

(68) (Example 36) The method of Example 35 comprising an effective one-time-per-bleaching-agent-exposure effective dose of up to 4% w/v ascorbic acid, 4% w/v alpha tocopheryl nicotinate, 4% w/v superoxide dismutase, 2% glutathione.

(69) (Example 37) The method of Example 35 comprising administering to an individual, topically on to the affected gingival tissue, an effective amount of the a synergistic Type 1-b antioxidant radiomimetic protective mixture in a gingival protectant gel, paste, suspension, rinse or powder base for up to an hour prior to use of high concentration dental bleaching chemicals, which is removed from the mouth prior to radiomimetic dental bleaching procedures.

(70) (Example 38) A timed-use synergistic Type 1-e method of radioprotection from ionizing radiation damage to the external skin comprised of an effective amount of the following radiodermal protectants: extracts of Hippophae rhamnoides (Sea Buckthorn), superoxide dismutase and bromelain.

(71) (Example 39) The method of Example 38 consisting of the preceding core composition with the addition to at least one or more of DFMO, papain, vitamin A and cooling.

(72) (Example 40) The method of Example 38 comprising an effective amount of each constituent, up to 8% w/v bromelain, 10% w/v sea buckthorn oil, 1% w/v DFMO, 8% w/v papain and 3% w/v vitamin A (retinal) and 5% superoxide dismutase, in a suitable dermal carrier such as a lotion, gel, ointment, plaster, soak or the like.

(73) (Example 41) The application of the mixture of Example 38 requires timed-use, carefully to be applied no more than 3 hours ahead of radiotherapy and the medicine physically removed just before radiotherapy. If the skin itself is not a target of radiotherapy, the dermal tissue temperature should be reduced to as low as tolerable levels (55 degrees Fahrenheit) immediately prior to radiotherapy for optimal dermal radioprotection.

(74) (Example 42) A synergistic timed-use Type II-a post-radiocontamination decorporation radiomitigation composition for oral administration. The mixture is for the simultaneous decorporation of radiocesium, radiostrontium, radiouranium, radioiodine, radiophosphorus and others from in vivo milieu of subjects affected by exposure to nuclear radiocontamination, said synergistic composition comprising both calcium alginate and psyllium husk powder.

(75) (Example 43) The composition of Example 42 consisting of the preceding core composition with the with the synergistic addition at least two or more of the following decorporation agents: chlorella, calcium citrate, activated charcoal, bentonite, green tea, Montmorillonite clay, aluminum hydroxide; phospho-soda (consisting of monobasic sodium phosphate monohydrate and dibasic sodium phosphate heptahydrate), sodium ferrocyanide, EDTA.

(76) (Example 44) The composition of Example 42 comprising an effective daily adult dose each up to: calcium alginate granules 5 g, psyllium husk powder 40 g, chlorella 20 g, calcium citrate 6 g, activated charcoal 100 g, bentonite 16 g, green tea extract 4 g, Montmorillonite clay 16 g, aluminum hydroxide 1.2 g, EDTA 4 g, phospho-soda 250 mg, sodium ferrocyanide 350 mg, ammonium perchlorate 490 mg/day.

(77) (Example 45) The utilization of Example 42 is timed for decorporation of gut-internalized radiocontaminants; the formulation being tailored to suspected types of radioisotopes, dosed as soon after discovery as possible and continuing indefinitely. Dosage forms may include any oral dosage form; suspension, tablets, capsules water, soda, soft drink or fruit juice or dry in the form of sprinkles or dry baking goods or as a recipe ingredient.

(78) (Example 46) A synergistic timed-use method of Type III-a radiorecovery hematopoietic treatment for oral administration comprised of copper chelate, ferrous sulfate, zinc gluconate, folacin, pyridoxine (vitamin B6), cyanocobalamin (vitamin B12), manganese chelate, and vitamin A with the addition of one or more of Ginkgo biloba (Ginkgo), 4-androstenedione, Ganoderma lucidum (Reishi), Lentinus edodes (Shiitake), Inonotus obluquus (Chaga), Grifola frondosa (Maitake).

(79) (Example 47) The composition of Example 46 comprising an effective daily adult dose up to: Manganese 15 mg, copper chelate 20 mg, ferrous sulfate 625 mg, zinc gluconate 50 mg zinc, vitamin A 25,000 IU, Ginkgo extract 2 g, 4-androstenedione 300 mg, folacin 800 mcg, pyridoxine 100 mg, Reishi extract 4 g, Shiitake extract 4 g, Chaga extract 4 g, Maitake extract 4 g as any oral formulation, such as tablets, capsules, in water, soda, soft drink or fruit juice, food, confection or dry powder and the like.

(80) (Example 48) The method in Example 46 comprising administering to an individual an effective amount to rebuild hematopoiesis and reduce bone marrow toxicity in cases of post-irradiation bone marrow suppression, particularly post-irradiation.

(81) (Example 49) The Type III-a radiorecovery composition of Example 46 timed for use soon after irradiation, within the first 24 hours, used daily for one week or continually as needed based on testing.

(82) (Example 50) A Type III-b post-radiation radiorecovery antifibrotic method of treating injury from ionizing radiation, the method comprising administration to an individual an effective amount of rosemary extract, Angelica sinensis (Dong Quai) and beta-carotene, plus one or more of the following radiorecovery antifibrotic agents: DMSO, glabridin, flaxseed oil, bromelain.

(83) (Example 51) The method of Example 50 comprising an effective daily adult dose of each up to: rosemary extract 5 g, bromelain 9 g, glabridin 60 mg, flaxseed oil 7 g. The composition provided as any oral formulation, such as tablets, capsules, in water, soda, soft drink or fruit juice, food, confection or dry powder and the like.

(84) (Example 52) The method in Example 50 whereby administration of the Type III-b radiorecovery antifibrosis treatment is delayed to day 5 post-radiation and used continually as indicated.

(85) (Example 53) A radiomitigation dye-tracer external decorporation clay wipe made of a fibrous wetted textured durable paper individually-wrapped disposable towelettes containing in the wetting solution PEG and one or more of Bentonite clay, French Green Clay, Fuller's Earth, Attapulgite, Pascalite, Zeolite, Montmorillonite or activated charcoal, with the possible addition of indigo dye, citric acid or other preservatives.

(86) (Example 54) The wipe of Example 53 whereby the composition of the wetting solution on the towelette w/v % is up to 12% PEG (polyethylene glycol), citric acid 4% or other suitable preservative, indigo dye 3%, with one or more of Bentonite clay, French Green Clay, Fuller's Earth, Attapulgite, Pascalite, Zeolite, Montmorillonite or activated charcoal 25%, qs water.

(87) The foregoing examples and formulations are presented for the purpose of illustration and are not intended to limit the scope of the invention. Variations and changes, which are obvious to one skilled in the art, are intended to be within the scope and nature of the invention as defined in the appended claims.

FEDERALLY SPONSORED RESEARCH

(88) Not Applicable

SEQUENCE LISTING OR PROGRAM

(89) Not Applicable

REFERENCED BY INVENTOR

(90) TABLE-US-00003 Stewart H. Webster, The Toxicology of Potassium and Sodium Iodates: Acute Toxicity in Mice Dr. S.J. Paxton-Pierson Protect Yourself From Radiation Dr. E. Bump Radioprotectors; Chemical, Biological, and Clinical Perspectives (Radiosensitization mechanism of riboavin in vitro, Liu et al, Sci China C Life Sci. 2002 Aug;45(4):344-52) (A. M. El-Tabey Shehata (1961) Effect of Combined Action of Ionizing Radiation and Chemical Preservatives on Microorganisms: I. Vitamin Kasa Sensitizing Agent. Radiation Research: July 1961, Vol. 15, No. 1, pp. 78-85.) (http://www.kyolic.com/research/allicinlallicin-is-a-highly-reactive-compoundl) (EFSA Panel on Food Additives and Nutrient Sources added to food (ANS) EFSA Journal 2010;8(12):1883 [49 pp.]) (J. Immunol. 141, 2714-2720 In vivo modulation of myelopoiesis by prostaglandin E2. IV. Prostaglandin E2 induction of myelopoietic inhibitory activity. Gentile, P. S, and Pelus, L. M.) (peer reviewed PubMed data for Prussian blue). (Chemical Abstract Service data for sodium ferrocyanide). (Selective Capture of Cesium and Thallium from Natural Waters and Simulated Wastes with Copper Ferrocyanide Functionalized Mesoporous Silica Thanopon, S. J Hazard Mater, Oct 15, 2010; 182 (1-3): 225-231). (Arena, Jay 1979 Fourth Edition, ISBN 0-398-03767-1 Charles C. Thomas Publisher, pg. 110 Poisoning Toxicology, Symptoms, Treatments) (Tohoku J Exp Med 1977 Jan;121(1):81-4 A comparative study of the effect of vitamin E-nicotinate and the combination of vitamin E and nicotinic acid on the hydrogen peroxide-induced platelet aggregation Higashi 0, Kikuchi Y)

RELATED U.S. PATENT DOCUMENTS

(91) TABLE-US-00004 US 7449451 B2 Radiation resistance; prevent tissue damage; pretreatment with oxidation resistant US 20040265231 A1 vitamins a, c and/or e at a dosage 5 to 10 fold over its regular dosage as a vitamin; reducing gastrointestinal and hemotopoietic symptoms US 7919525 B2 Radiation protection by gamma-tocotrienol CA 2792913 A1 Improved stable aqueous formulation of (e)-4-carboxystyryl-4- chlorobenzyl sulfone WO 2009126866 A2 Delta-tocotrienol as a radioprotective countermeasure agent CA 2613086 A1 Anti-inammatory, radioprotective, and longevity enhancing capabilities of cerium oxide nanoparticles WO 2005020935 A2 Method and composition of administering radioprotectants US 20130158106 A1 Tocopherol derivatives and methods of use US 6340746 B1 Thiolamine or selenolamine conjugate with antioxidant vitamin; nontoxic EP 2579943 A1 (text from Intracavity balloon catheter W02011156697 A1) US 20110306825 A1 Intracavity balloon catheter EP 2211857 B1 Use of quaternary pyridinium salts for radioprotection WO 2007150049 A2 Lactoferrin as a radioprotective agent US 20110172179 A1 Micronutrient formulations for radiation applications US 6805880 B1 Pharmaceutical delivery system for vitamin C and vitamin E and use of a combination of vitamin C and E for preventing or treating conditions involving oxidative stress P 0219455 A2 Pharmaceutical and cosmetic compositions containing N-acetylcsteine US 5248697 A For treatment of radiation associated oxidative damage in tissue US 4985241 A Therapeutic combination of free-radical scavenger and tumor necrosis factor WO 1989004825 A1 New derivatives of cysteine, processes for their preparation and their use EP 0269017 B1 Therapeutic combination of free-radical scavenger or metabolic inhibitor and biologically active protein EP0284105 B1 Human manganese superoxide dismutase and methods of US 5192524 A Captopril as a cancer chemopreventive agent US 4961926 A Methods for prevention and treatment of mucositis with granulocyte colony stimulating factor WO 1987001387 A1 A superoxide dismutase US 4968616 A Superoxide dismutase derivatives, method of producing same and medicinal use of same EP 0292321 B1 Acylated derivative of superoxide dismutase and composition containing same WO 1992019224 A3 Anti-free-radical topical composition based on a superoxide dismutase and a phosphonic derivative US 4657928 A Organic copper complexes as radioprotectants US 4676979 A Injection of polyoxyethylene glycol or polyvinylpyrorolidone EP 0546063 A1 Toxic agent protective compounds, compositions and uses US 4780238 A Natural chelating agents for radionuclide decorporation US 5206008 A Using androstene(diol or triol) US 7553829 B2 Administering delta 5-androstene-3 beta-o1-7,17 dione and metabolizable precursors thereof, such as the 3-beta EP 1208842 A2 Regulation of the immune system US 4659700 A Chitosan-glycerol-water gel DE 19712699 C2 A method for producing rapid wound dressings with wound care active substances US 5888520 A Composition, barrier film, and method for preventing contact dermatitis WO 2007055481 A1 Sustained release film formulationfor healing wound comprising epidermal growth factor US 20130012582 A1 Vinylic mask with peel-off effect for topical use containing high concentrationsof retinoic acid US 7449451 B2 Radiation resistance; prevent tissue damage, pretreatment with oxidation resistant WO 2013152055 A1 Method and composition for ameliorating the effects for a subject exposed to radiation or other sources of oxidative stress US 7435725 B2 Oral compositions and methods for prevention, reduction and treatment of radiation injury US 7935366 B2 mixture with Calcium Iodate, and Calcium Carbonate for removal of all three radionuclides Cesium, Strontium, Iodine US 6753325 B2 Comprises vitamin d3 for controlling cell differentiation and/or cell proliferation US 7250445 B1 Anti-oxidant suppository for treating radiation proctopathy and other anorectal disorder; US 5667791 A X-ray induced skin damage protective composition US 6841578 B2 Administering a an inhibitor of nuclear factor-kappa B to an individual undergoing or preparing to undergo a treatment for cancer; particularly ulcerative mouth tissue; antiinflammatory agents; side effect reduction US 6576269 B1 Treating open skin lesions using extract of sea buckthom WO 2011056288 A1 Functionalized nanomaterials for dermal decorporation, chelation, therapy, and sorbent dialysis of radiounuclides and US 5494935 A Chelation of heavy metals from humans and animals using polyaminocarboxylic acids US 4780238 A Natural chelating agents for radionuclide decorporation US 7935366 B2 mixture with Calcium Iodate, and Calcium Carbonate for removal of all three radionuclides Cesium, Strontium, Iodine US 5288718 A Method for decorporating radioactive isotope from living US 7638485 B2 Modulating apoptosis US 7737320 B1 Composition suitable for decontaminaing a porous surface contaminated with cesium WO 2012030429 A1 Topical applicator composition and process for removal of radionuclides from radiologically contaminated dermal us 4659700 A Chitosan-glycerol-water gel DE 19712699 A1 Rapid dressing for wounds, used to improve environment of US 5888520 A Composition, barrier film, and method for preventing contact dermatitis WO 2007055481 A1 Sustained release film formulation for healing wound comprising epidermal growth factor US 20130012582 A1 Vinylic mask with peel-off effect for topical use containing high concentrations of retinoic acid 7,449,451 Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing WO 2013152055 A1 Method and composition for ameliorating the effects for a subject exposed to radiation or other sources of oxidative 7,435,725 Oral compositions and methods for prevention, reduction and treatment of radiation injury US7935366 B2 Calcium Potassium Ferrocyanide 6,753,325 Composition and method for prevention, reduction and treatment of radiation dermatitis 6,663,850 Inhibition of ceramide for the prevention and treatment of oral mucositis induced by antineoplastic drugs or radiation 7,250,445 Anti-oxidant suppository for treating radiation proctopathy and other anorectal disorders 5,667,791 X-ray induced skin damage protective composition 6,841,578 Treatment and prevention of mucositis in cancer patients 6,576,269 Treating open skin lesions using extract of sea buckthom W02011056288 A1 Functionalized nanomaterials for dermal decorporation, chelation, therapy, and sorbent dialysis of radiounuclides and 5,494,935 Chelation of heavy metals from humans and animals using polyaminocarboxylic acids 5,403,862 Administering partially lipophilic polyaminocarboxylic acid chelating agent 4780238 Natural chelating agents for radionuclide decorporation 5,288,71 Method for decorporating radioactive isotope from living US 7737320 B1 Composition suitable for decontaminating a porous surface contaminated with cesium WO 2012030429 A1 Topical applicator composition and process for removal of radionuclides from radiologically contaminated dermal